A phase I hexaminolevulinate [hexyl aminolevulinate] (HAL) dose-finding study applying different formulations to the cervix in healthy volunteers

Trial Profile

A phase I hexaminolevulinate [hexyl aminolevulinate] (HAL) dose-finding study applying different formulations to the cervix in healthy volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Hexyl aminolevulinate (Primary)
  • Indications Bladder cancer; Cervical intraepithelial neoplasia; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors PhotoCure
  • Most Recent Events

    • 15 Jan 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top